Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Aptamers: an emerging class of therapeutics.

Publication ,  Journal Article
Nimjee, SM; Rusconi, CP; Sullenger, BA
Published in: Annu Rev Med
2005

Numerous nucleic acid ligands, also termed decoys or aptamers, have been developed during the past 15 years that can inhibit the activity of many pathogenic proteins. Two of them, Macugen and E2F decoy, are in phase III clinical trials. Several properties of aptamers make them an attractive class of therapeutic compounds. Their affinity and specificity for a given protein make it possible to isolate a ligand to virtually any target, and adjusting their bioavailability expands their clinical utility. The ability to develop aptamers that retain activity in multiple organisms facilitates preclinical development. Antidote control of aptamer activity enables safe, tightly controlled therapeutics. Aptamers may prove useful in the treatment of a wide variety of human maladies, including infectious diseases, cancer, and cardiovascular disease. We review the observations that facilitated the development of this emerging class of therapeutics, summarize progress to date, and speculate on the eventual utility of such agents in the clinic.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annu Rev Med

DOI

ISSN

0066-4219

Publication Date

2005

Volume

56

Start / End Page

555 / 583

Location

United States

Related Subject Headings

  • Viral Proteins
  • Transcription Factors
  • Oligonucleotides
  • Humans
  • HIV Infections
  • General & Internal Medicine
  • Gene Library
  • Drugs, Investigational
  • Drug Evaluation, Preclinical
  • Drug Design
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005). Aptamers: an emerging class of therapeutics. Annu Rev Med, 56, 555–583. https://doi.org/10.1146/annurev.med.56.062904.144915
Nimjee, Shahid M., Christopher P. Rusconi, and Bruce A. Sullenger. “Aptamers: an emerging class of therapeutics.Annu Rev Med 56 (2005): 555–83. https://doi.org/10.1146/annurev.med.56.062904.144915.
Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med. 2005;56:555–83.
Nimjee, Shahid M., et al. “Aptamers: an emerging class of therapeutics.Annu Rev Med, vol. 56, 2005, pp. 555–83. Pubmed, doi:10.1146/annurev.med.56.062904.144915.
Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med. 2005;56:555–583.

Published In

Annu Rev Med

DOI

ISSN

0066-4219

Publication Date

2005

Volume

56

Start / End Page

555 / 583

Location

United States

Related Subject Headings

  • Viral Proteins
  • Transcription Factors
  • Oligonucleotides
  • Humans
  • HIV Infections
  • General & Internal Medicine
  • Gene Library
  • Drugs, Investigational
  • Drug Evaluation, Preclinical
  • Drug Design